This review reveals how adipokines impact Alzheimer's disease in obesity, suggesting natural compounds and antidiabetic agents may provide therapeutic options.
Key Points
Adipokines are crucial in linking metabolic dysfunction and cognitive decline, notably in Alzheimer's disease.
Evidence suggests that natural compounds can modulate adipokine signaling, improving metabolism and reducing AD-related pathology.
Antidiabetic agents like GLP-1 receptor agonists tend to enhance protective adipokines and lower inflammation.
Targeting the adipokine–inflammation–metabolism axis presents new strategies for managing obesity-associated Alzheimer's disease.